Michael Baker’s mysterious data

The architect of NZ’s elimination strategy for Covid19, Michael Baker, criticised former “Bachelor” star Naz Khanjani for implying her mild experience of Covid19 was the typical experience.

He said her comments were “dangerous” misinformation, and a “fallacy”. Yet a reality TV star show had it right – her experience is very, very, typical.

So we have some questions for Mr Baker from the strange statistics he gave to the media.

  • If his 1% mortality figure is correct, then why is the WHO publishing statistics indicating that the median is 5 times lower?

https://www.who.int/bulletin/online_first/BLT.20.265892.pdf

Is he saying the WHO and Ioannidis is wrong?

The 1% figure provided by Baker led Prof. Rod Jackson to predict 60,000 deaths in Sweden.

https://www.nzherald.co.nz/nz/rod-jackson-has-sweden-made-a-fatal-mistake-with-covid-19-coronavirus/RUR7CV376CXFC4Q2M7J7YAYW6M/

Currently, there are about 9,300 deaths in Sweden, again indicating that the figure is grossly inflated.

  • If Baker is right and the virus is 20x more deadly than the flu, how can it be that Denmark, Estonia, Finland, Germany, Malta, Norway, and Northern Ireland have had no increase in overall mortality, despite widespread exposure to the virus?

https://www.euromomo.eu/graphs-and-maps/

Also, if the virus is 20x more deadly than the flu, then why are the observed deaths in New Zealand occurring with an age profile that is the same as natural death occurring in past years? Surely, if the virus were so deadly, it would shorten lives, as the 1918 flu epidemic did?

https://www.covidplanb.co.nz/our-posts/is-new-zealands-covid-19-story-past-its-use-by-date/

  • Does Baker consider that part of the chaos happening overseas is due to the policies enacted, and not the virus itself?

https://collateralglobal.org/

Ivermectin now a proven Covid treatment

A WHO-commissioned meta-analysis of Ivermectin shows that using this generic medicine in hospitals leads to a 83% reduction in covid mortality (95% CI 65%-92%). See: https://www.youtube.com/watch?v=yOAh7GtvcOs
The WHO is understood to be waiting for the results this month from three trials before issuing a recommendation.
The position of NZ’s Ministry of Health cautioning against using Ivermectin has not changed since April 2020, despite a consistent growth in studies showing effectiveness.
On the basis of the studies to date, Covid Plan B urges the Ministry of Health to immediately delete its nine-month old caution against using Ivermectin to treat Covid19. A new formal position can be release following advice from the WHO.
Internationally, front line doctors have been frustrated and even abused by authorities and politicians in their efforts trying to make people aware of the effectiveness of Ivermectin. https://www.hsgac.senate.gov/imo/media/doc/Testimony-Kory-2020-12-08.pdf
Covid Plan B contrasts the MOH warning against studies that emerged in favour of Ivermectin, with its decision to buy respirators at the start of the pandemic without clear evidence of their effectiveness. It now appears that respirators harmed some Covid19 patients.
Panic from politicians and policy makers has driven over-reactions and bad decisions. Acting without evidence has caused more harm than good.

Debate of 2020: Thornley vs Baker on Covid19 response

Finally, the debate New Zealand should have had in March 2020. Simon Thornley and Michael Baker discuss using elimination and lockdowns against Covid19.

We correct NZHerald story about NZ Journal of Primary Health Care

Our letter to the NZHerald regarding the recent story on our NZ Journal of Primary Health Care (https://www.publish.csiro.au/hc/Fulltext/HC20132).
Vaccine caution
We recently wrote a scientific article in a leading medical journal which featured prominently in a Herald news report.
Our article was not “rebuked” by the scientific adviser of the Ministry of Health. As part of the usual scholarly review process, the editor of the journal asked the ministry for comment. When one group raises questions about the work done by another, the latter is always given an opportunity to respond.
The article and the response are available for any reader.
The article seriously mischaracterises our views about Covid-19 vaccines. Our letter urges caution about the speed of the rollout of the Covid-19 vaccine, since historic vaccines for respiratory viruses, such as swine flu, have been associated with adverse effects. The associate editor of the British Medical Journal, Peter Doshi, has raised questions about the efficacy of current vaccines. None of them yet have evidence of success in reducing severe infection (hospital admission, ICU, or death) or interrupting transmission (person-to-person spread). At least, the trials could not test for these, given the compressed time-frame.
Developing and distributing these vaccines to seven billion people of the world is a non-trivial task.
This does not make the vaccines useless but does raise legitimate questions about basing our border policy on the effectiveness and wide availability of vaccines.
Finally, we caution against the types of ad hominem attacks reflected in this article. This is not the way to undertake either good science or good policy.
Simon Thornley, Ananish Chaudhuri, Gerhard Sundborn, Grant Schofield, Auckland.

The fallacy of Covid19 ‘fact checking’

Covid Plan B was ‘fact checked’ as ‘misleading’ for publishing on Facebook our article which used the existing conventional standard of statistical interpretation to find that a Danish study on mask wearing meant there was no significant benefit to wearing a mask against Covid19.

This so-called ‘fact check’ used a non-conventional approach which would mean that any study showing no significant effect of the studied intervention would mean the intervention does work.

This is clearly astounding. It reverses decades of scientific interpretation. It defies common-sense. But that is what ‘fact checking’ has become in the Covid19 era: a means of upholding the establishment policy position (using non-scientist media staffers).

It is not a means of checking facts. It is a means of denying them.

We outlined this deeply worrying development in an article in the British Medical Journal. Danish mask study: masks, media, fact checkers, and the interpretation of scientific evidence | The BMJ

Should we abandon convention altogether? If we did, we may eventually promote ineffective treatments. As an example, electrostimulation, laser therapy, and acupuncture are not generally thought to improve smoking cessation success, yet several promising pooled effects were calculated in a meta-analysis, although the majority were not“statistically significant.”

The tone of the“fact checking”piece that apparently supports mass masking as having a“small protective effect”over a conventional interpretation  as“misleading”turns usual scientific practice on its head. Pointingto observational evidence to contradict trial results is another subversion of usual epidemiological practice. While this may seem trivial, it is a subtle distortion of results and the politicisation of evidence in the covid-19 era.

Full PDF here: bmj.m4919.full

 

NZ’s solo effort on elimination

A short piece from us published in NZ Journal of Primary Health Care.

https://www.publish.csiro.au/hc/Fulltext/HC20132

How many more lockdowns, billions of dollars and social and health harm is an acceptable price to pay before this misguided and expensive strategy is abandoned? We implore Prime Minister Jacinda Ardern, Director-General of Health Dr Ashley Bloomfield, and fellow health advisors to reflect on the points raised in this paper and to abandon elimination as a strategy and the use of lockdowns. We believe that future policy should return to the initial approach that was taken. That is to reduce transmission of COVID-19 through reasonable use of infection control, to maintain capacity in our hospitals and intensive care, while focusing public health and infection control efforts to protect the frail and elderly of our community.

No mortality difference between Sweden and Norway, but Norway result came at huge cost

An important study (preprint at time of this post) shows similar mortality rates in Sweden and Norway despite different national responses to the Covid19 virus. But critically, Sweden’s mortality outcome came at a much cheaper economic cost.
Despite an order of magnitude difference in case-fatality rates in Sweden (higher) compared to Norway, the two countries had very similar overall mortality profiles.
There was a big difference though in national costs. Norway’s more restrictive policies resulting in public spending 2.6-fold more than Sweden (Norway: 4,176 Euros per person & Sweden 1,580 per person) during the epidemic.
It also reveals that the spike in mortality in Sweden which had caused consternation, and some unfortunate glee among pro-lockdown observers, was most likely due to ‘displaced mortality’ from low mortality in earlier seasons. Norway had no overall mortality spike.

Lead vaccines: answers needed

As lead vaccines announce good results and intentions to register for fast-tracked safety authorisation in EU and the US, immunologist Byram Bridle, reminds us of questions that they will need to answer:

Dr. Byram Bridle, PhD, Associate Professor of Viral Immunology, University of Guelph, Ontario, Canada

  1. How many of the total study subjects are being reported on? Partial results can range from being representative of the entire data set to being biased.
  2. How many study subjects had detectable immune responses and what was the magnitude?
  3. Were there antibody responses in the respiratory tract, which is where SARS-CoV-2 infects, and did these antibodies efficiently neutralize the virus?
  4. Were SARS-CoV-2-specific T cells induced? A balanced anti-viral response should include antibodies to prevent infection and T cells to kill viruses that get past the antibody barrier.
  5. Did the immune responses have a ‘Th1’ or ‘Th2’ bias? The former type of immune response is optimal against viruses, the latter is usually sub-optimal and sometimes even dangerous in the context of respiratory viral infections.
  6. Did the vaccine confer long-term immunological memory? A prophylactic vaccine may be useless without this. If immunological memory is short-lived, vaccinated individuals could become susceptible to infection before enough people are immunized to achieve ‘herd immunity’. Another term for this is ‘duration of immunity’ (i.e. how long does immunological protection last?)
  7. How did the vaccine perform in senescent animals and/or elderly humans? Those most in need of protection against COVID-19 are the elderly and immunocompromised.
  8. How was safety assessed and what were the results?
  9. Have the results been published for review by other scientists? If not, when? It is recommended to publish in open-access journals, which are available to the public. Comments merely reflect opinions unless there are validated data to back them up.
  10. Related to #6 above, what is the plan to manufacture and roll-out enough vaccine doses to achieve herd immunity in any given country? What is the realistic timeline for this? If >1 year, there is no way to know if COVID-19 vaccines will confer protection for this long because they didn’t exist one year ago. The development of every historical vaccine took >4 years, so there were years-worth of ‘duration of immunity’ data. For example, optimistic projections suggest ~1 billion doses might be possible by the end of 2021, but for two-dose regimens, that means only 500 million people could potentially be vaccinated in just over one year. With the global population at 7.8 billion people, that represents only 6% of the world’s population. The lowest estimate to achieve herd immunity is 60%.
  11. How will equitable distribution of vaccines be accomplished? For example, pre-order waiting lists seem to be dominated by developed countries; are any developing countries on these waiting lists?
  12. What is the cost of a full vaccine regimen going to be? Is it affordable for developing countries? Some epidemiologists have predicted that efficient roll-out of vaccines to developing countries will require the price to be <$6 US.
  13. Storage conditions for vaccines could impact distribution and market competitiveness. What data are available to support the claimed storage conditions? For example, the default storage temperature for RNA in research laboratories is -80o This is based on a plethora of scientific evidence that RNA is more stable at this temperature compared to -20oC.

Danish mask study result; no statistical difference from not wearing one

Only two days after the NZ government announced mandatory mask wearing rules the much awaited Danish mask study was published, and it is conclusive; masks give no statistically significant protection from Covid19.

Here’s the study: https://www.acpjournals.org/doi/10.7326/M20-6817

Results:

A total of 3030 participants were randomly assigned to the recommendation to wear masks, and 2994 were assigned to control; 4862 completed the study. Infection with SARS-CoV-2 occurred in 42 participants recommended masks (1.8%) and 53 control participants (2.1%). The between-group difference was −0.3 percentage point (95% CI, −1.2 to 0.4 percentage point; P = 0.38) (odds ratio, 0.82 [CI, 0.54 to 1.23]; P = 0.33). Multiple imputation accounting for loss to follow-up yielded similar results. Although the difference observed was not statistically significant, the 95% CIs are compatible with a 46% reduction to a 23% increase in infection.

Conclusion:

The recommendation to wear surgical masks to supplement other public health measures did not reduce the SARS-CoV-2 infection rate among wearers by more than 50% in a community with modest infection rates, some degree of social distancing, and uncommon general mask use. The data were compatible with lesser degrees of self-protection.

Below is our Euler diagram summarising the findings of the Danish mask trial.

The small difference in event proportions, with a slightly higher proportion in the control group, was not distinguishable from a chance finding (“not statistically significant” is the boffin term).

This is probably the best evidence we have up to now, which is disappointing for advocates of mask use to prevent covid-19 infection. This evidence is consistent with previous trials which found no effect in trials designed to assess the effect of masks to prevent the community transmission of influenza.

An uncompromising expression of the Covid-skeptic position

Even our jaws dropped at this compelling, powerful, uncompromising statement from a Canadian doctor to the Edmonton City Council Community and Public Services Committe.

Hodkinson is the CEO of Western Medical Assessments, and has been the company’s medical director for over 20 years. He received his general medical degrees from Cambridge University in the U.K., and then became a Royal College certified pathologist in Canada (FRCPC) following a residency in Vancouver.

He also taught at the University of Alberta and runs MutantDx, a molecular diagnostics company in North Carolina.

Dr Hodkinson – Canada